Weekly Health Industry Report: XtalPi Secures Strategic Partnership with China Construction Bank; Bio-Thera Solutions Advances Overseas Monoclonal Antibody Licensing

XtalPi Signs Strategic Cooperation Agreement with China Construction Bank, Secures RMB 5 Billion Credit Line

XtalPi Signs Strategic Cooperation Agreement with CCB Shenzhen Branch, Secures RMB 5 Billion Credit Line

Bio-Thera's Overseas Licensing Collaboration Achieves Significant Progress

Bio-Thera Signs Overseas Licensing Agreement with Gedeon Richter for Ustekinumab, Receives $10 Million Upfront Payment to Boost R&D and Internationalization Strategy. Ustekinumab is a key drug for psoriasis treatment, and Bio-Thera has advanced its commercialization in multiple regions globally. (Source: China Pharmaceutical Network)

Nanjing Pengbo and Lixin Pharmaceutical Technology Reach Licensing Agreement

GenScript Biotech's Nanjing subsidiary Pengbo reaches global licensing agreement with Lixin Pharmaceutical Technology, granting Lixin rights to develop, manufacture, and commercialize anti-PD-1 single-domain antibody-related products, with potential for upfront payments, milestone payments, and sublicensing revenue. Meanwhile, Merck & Co. enters into an exclusive global license with Lixin for the investigational drug LM-299 containing this antibody. (Source: Zhitong Finance)

Bright Eye Deepens Innovation Technology Cooperation

Bright Eye and Johnson & Johnson Vision, a global leader in eye health, signed the 2025 Strategic Cooperation Agreement on the morning of November 6. Both parties will work together to promote technological innovation and development in China's ophthalmology field, providing high-quality ophthalmic medical services to a wide range of patients. According to the agreement, both parties have reached an in-depth cooperation consensus: First, they will jointly promote the full coverage of PanOptix and the comprehensive development of refractive cataract surgery at Bright Eye hospitals to meet the high-end needs of more patients; Second, they will collaborate to establish presbyopia clinics, demonstration centers for refractive cataract surgery, and standardized astigmatism management demonstration centers, benefiting patients’ eye health throughout their entire life cycle; Third, they will comprehensively advance the construction of an ophthalmology talent team in the cataract field, actively empowering young and middle-aged doctors to enhance their clinical surgical skills, and providing more patients with clear and excellent postoperative visual quality. (Source: Arterial Network)

Xingpu Tai Completes Tens of Millions of Yuan in Strategic + Round Financing

Recently, Taizhou Xingputai Biopharmaceutical Co., Ltd. ("Xingputai" for short) announced the completion of a strategic financing round worth tens of millions of RMB. This round of financing was jointly invested by Jiangsu Taifeng Chemical Co., Ltd., the world's leading dye industry leader, and Fengtide Enterprise Management, with Source One Capital serving as the exclusive financial advisor for this round of financing. Through this financing, Jiangsu Taifeng and Xingputai will fully leverage their respective strengths and resources to jointly support the continuous and stable development of Xingputai in the Taixing Economic Development Zone. Both parties will also explore and promote the smooth implementation and commercial operation of cooperative projects. (Source: Arterial Network)

Tongrui Biologics Completes Over $100 Million Series A+ Financing

As an innovative enterprise in the field of radiopharmaceuticals, Tongrui Biopharmaceuticals (Chengdu) Co., Ltd. ("Tongrui Biopharmaceuticals" for short) announced the completion of an over 100 million US dollar A+ round of financing. This round of financing was jointly led by Shenzhen Capital Group's Manufacturing Transformation and Upgrading New Materials Fund (referred to as "Shenzhen Capital Group") and Tylon Investment, with participation from multiple well-known institutions and industry players such as GL Ventures (Gaoling Venture Capital), 3SBio Inc. (01530.HK), Guanghua Wutong, and a certain well-known industrial investment institution. WinX Capital served as the exclusive financial advisor for this transaction. (Source: Arterial Network)

Impulse Pharmaceuticals Announces Successful Completion of RMB 250 Million D++ Financing Round

Nanjing IMPACT Therapeutics Co., Ltd. ("IMPACT Therapeutics"), an innovative drug research and development company focusing on the mechanism of synthetic lethality in oncology, is pleased to announce the successful completion of its RMB 250 million D++ round of financing. This round of financing was jointly invested by a globally renowned industrial investment institution and a well-known insurance fund. Zhoudu Capital served as the exclusive financial advisor for this round of financing. (Source: Arterial Network)

Tianwu Technology Completes Over 100 Million Yuan in Series A Financing

On November 15, Tianwu Tech, an internationally leading AI protein design company, announced the completion of its Series A financing round exceeding 100 million yuan. This round was led by Qiming Venture Partners, with participation from investors including Yonghua Investment, Jingtao Capital, and existing shareholder Bencao Capital, among other institutions. The funds raised will primarily be used for the development of self-research projects and the continuous iteration and upgrading of AccelProtein™, a general artificial intelligence for protein design (originally developed by the Hong Liang team at Shanghai Jiao Tong University as part of the Pro series AI), to ensure that Tianwu Tech maintains a leading position in global technological innovation and market competitiveness. (Source: Arterial Network)

Heavyweight Injectable Surges 6428%, 177 Drugs Shine Brightly

Latest data from MiNe Network shows that the sales scale of Western medicines (chemical drugs + biologics) in China's urban physical pharmacies maintained positive growth in the first half of 2024, reaching 89.8 billion yuan, with eight major categories showing positive growth. A total of 177 Western medicine brands exceeded 100 million yuan in sales, with Qingdao Shuangwhale Pharmaceutical’s Vitamin D Drops regaining the top spot. In contrast, Yichang Dongyangguang Yangtze River Pharmaceutical’s Oseltamivir Phosphate Granules, known as the "flu wonder drug," plummeted by 52%. Ten brands with sales over 100 million yuan achieved growth rates exceeding 100%, with Nanjing Shunxin Pharmaceutical's Rituximab Injection from Zhengda Tianqing surging by an astonishing 6428%. From a group perspective, multinational pharmaceutical companies remain strong, while domestic players such as Zhengda Pharmaceuticals, China Resources Sanjiu, Hengrui Medicine, and CSPC Holdings successfully entered the TOP15 list. (Source: MiNe Network)

New Increment Policy: Price Project Initiation Supports the Development of Mental Health Treatment Services

To further advance the progress of psychotherapy techniques, promote the comprehensive and diversified development of medical institutions, and effectively address the shortcomings in psychiatric treatment, the National Healthcare Security Administration recently issued the "Guidelines for the Establishment of Psychiatric Treatment Medical Service Price Items (Trial)." These guidelines standardize psychiatric treatment pricing items to enhance the quality and level of healthcare services provided to the public. Taking into account factors such as the severity of patients' psychological issues, the implementing entity, intervention methods, and treatment objectives, a distinction is made between "psychotherapy" and "psychological counseling" in price setting. To accommodate variations in treatment duration for different patients and methods, psychotherapy is charged by the "hour" to ensure the integrity of the treatment and avoid time constraints affecting treatment outcomes. (Source: National Healthcare Security Administration)